The 1st China Pharmaceutical Innovation Conference (CPIC), hosted by TONACEA, will be grandly held from July 22 to 24, 2026, at the National Exhibition and Convention Center (Shanghai).

Benchmarking the J.P. Morgan Healthcare Conference, CPIC aims to establish a new paradigm of "Chinese Innovation – Global Translation – Shanghai Transaction." As the "premier window" for global capital and enterprises to gain insight into China's innovation ecosystem, and as the "core hub" for Chinese pharmaceutical companies to upgrade, go global, and connect with the world, CPIC is set to become the definitive barometer for annual investment and collaboration in the global health industry. The conference will feature dozens of dedicated sessions covering numerous hot topics and future directions in health industry innovation investment and globalization.

Rooted in Shanghai, Connecting the World. A special China-Japan Collaboration Forum has been established at this conference, inviting several distinguished leaders from the investment and industrial sectors of both China and Japan to share insights on investment and development opportunities in Japan. More speakers will be announced soon. Stay tuned!

Speaker Introductions

Hiroki Narita

CEO of Daiwa Corporate Investment (DCI) and Director of Daiwa Securities Group

A leading venture capitalist in Japan's life sciences sector. He has completed 24 investments in the biotechnology field, successfully guiding over 15 portfolio companies to IPO or M&A, demonstrating outstanding performance in nurturing companies from startup stage to public markets. Additionally, he serves as a specially appointed professor at Tohoku University, the first Japanese institution of higher education designated as an "International Excellence Research University" under national policy.

Through industry-academia collaboration, Mr. Narita actively supports the construction of innovation ecosystems. At the CPIC2026 Japan-China Cooperation Forum, he will speak as a leader in Japan's biotechnology investment sector, covering DCI's investment strategy, investment track record in Japan, Taiwan, and Korea, Japan's biotechnology advancement initiatives, and possibilities for cooperation in the Japan-China life sciences field, providing a valuable opportunity to deepen collaborative relationships with Chinese companies and investment institutions.

Issei Tsukamoto

Global Head of Business Development, Astellas Pharma

Fully responsible for all partnership activities at Astellas Pharma, ranging from venture investment, R&D collaboration, licensing to mergers and acquisitions. Prior to joining Astellas, he served as Head of Japan Business Development at Takeda Pharmaceutical Company, where he led multiple major business development transactions, including the transformation of Japan's product portfolio following the acquisition of Shire. Furthermore, he possesses 11 years of drug discovery and R&D experience, providing a comprehensive perspective spanning from early-stage research to commercialization.

Based on this extensive industry experience, at the CPIC2026 Japan-China Cooperation Forum, Dr. Tsukamoto will speak as Astellas' highest-ranking business development executive on the company's strategic priority areas, required technologies and assets, and partnership models (such as in-licensing, co-development, and M&A). Through a dedicated pitch session, he will recruit partners for collaborative business development through Japan-China corporate cooperation and alliances.

Keiji Kawamoto

Representative, Kawamoto BioBusiness Partners / Senior Advisor, Shanghai Deband Law Firm (Shanghai)

An expert in cross-border innovative drug business development and partnership negotiations between China and Japan. He began his career at Fujisawa Pharma (now Astellas Pharma), where for 25 years he advanced international business through licensing, joint ventures, and a three-year assignment in the United States. In 2005, he founded Kawamoto BioBusiness & IP Firm in Japan, focusing on IP strategy, business model structuring, and contract negotiation representing Japanese companies in deals with Western pharmaceutical firms. He also served as an outside director for three companies.

Since relocating to Shanghai in 2012, he has collaborated with Chinese and Japanese companies to facilitate cross-border innovative drug partnership arrangements. Recently, together with Chinese partners, he established the "Japan-China BioPharma Fast-Track Cooperation Platform" to promote collaboration and cross-border alliances between Japanese and Chinese companies. As a promoter of Japanese participation in CPIC2026, he will serve as the Japanese organizer of the 2026 Japan-China Cooperation Forum, dedicated to deepening mutual understanding and advancing partnerships in the innovative drug sector.

Dr. RuiPing Dong

Founder of RealOne Medicines

A senior expert in Japan's life sciences and oncology drug development, Dr. Dong has extensive experience in Japan's new drug development and regulatory affairs. Throughout his career, he has led the R&D and Japan market approval of multiple innovative targeted anti-tumor drugs and successfully brought several breakthrough therapies to the Japanese market. He has held key senior positions in global top multinational pharmaceutical companies including AstraZeneca, Bristol-Myers Squibb, and Merck & Co., with profound expertise in global drug R&D, regulatory registration, and Asia-Pacific commercialization.

Dr. Dong obtained his Ph.D. from Kyushu University School of Medicine, Japan, and later conducted research at Dana-Farber Cancer Institute, Harvard. He has long been committed to Sino-Japanese pharmaceutical industry exchanges and industry-university-research cooperation.

At the CPIC2026 China-Japan Cooperation Forum, as a distinguished professional deeply engaged in Japan's innovative pharmaceutical industry, Dr. Dong will deliver a speech focusing on the R&D layout of innovative oncology drugs, practical experience in Japan's regulatory approval, achievements in global industrialization, and cooperation prospects in the life sciences and biopharmaceutical fields between China and Japan, providing valuable insights and opportunities for deepening industrial collaboration between Chinese and Japanese pharmaceutical enterprises.